HDAC3-IN-7
HDAC3-IN-7 (Compound 8ae) is a selective HDAC3 inhibitor with an IC50 value of 311 nM. HDAC3-IN-7 degrades PD-L1 through the lysosome pathway mediated by Cathepsin B, exerting activities such as inhibiting tumor cell proliferation, migration, and invasion. HDAC3-IN-7 is promising for research of cancers[1].
Product Specifications
UNSPSC
12352211
Target
HDAC; PD-1/PD-L1
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=C(NNCCC)CCCCCCNC(C1=CN=C(C2=CC=C(NC(OC(C)(C)C)=O)C=C2)S1)=O
Molecular Formula
C25H37N5O4S
Molecular Weight
503.66
References & Citations
[1]Hu Z, et al. Design, synthesis and bioevaluation of novel hydrazide derivatives as enhancers of immunotherapy and DNA-damage response in antitumor therapy. Eur J Med Chem. 2025 Apr 7;291:117601.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC3
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC741081-100 1x 100 µL
CD45RO (190-2F2.5), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040994-500 1x 500 µL
TNF alpha (J2D10), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402026-100 1x 100 µL
CD45 / LCA (Leucocyte Marker) (PTPRC/1783R + PTPRC/1975R), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details